whether
transmit
water
air
blood
anim
vector
insect
rodent
viral
infect
still
remain
signific
threat
life
worldwid
besid
common
viral
ill
childhood
measl
rubella
varicella
mump
influenza
sever
acut
respiratori
syndrom
sar
hemorrhag
fever
yellow
fever
ebola
dengu
acquir
immun
defici
syndrom
aid
chronic
hepat
b
c
exampl
sever
viral
diseas
henc
fight
viral
contamin
actual
great
concern
shown
number
prevent
approach
implement
among
routin
viral
monitor
environment
drink
water
detect
waterborn
virus
enter
virus
eg
norovirus
caus
acut
gastrointestin
ill
limit
waterborn
viral
outbreak
implement
emerg
air
decontamin
technolog
prevent
aerosol
transmiss
infect
indoor
environ
develop
effect
robust
procedur
ensur
viral
safeti
biolog
blood
compon
plasma
deriv
manufactur
control
vector
mosquito
reduc
potenti
bite
nuisanc
transmiss
vectorborn
pathogen
eg
dengu
yellow
fever
virus
individu
level
besid
good
hygien
practic
protect
measur
includ
use
individu
equip
facemask
reduc
spread
airborn
virus
pandem
potenti
eg
influenza
viru
iav
condom
prevent
transmiss
human
immunodefici
viru
hiv
sexual
intercours
els
steril
syring
needl
reduc
transmiss
bloodborn
virus
eg
hiv
hepat
bhepat
c
viru
hbvhcv
among
inject
drug
user
activ
immun
ie
vaccin
indispens
treatment
prevent
viral
infect
vaccin
childhood
viral
ill
influenza
polio
hepat
ab
routin
administ
search
effici
safe
prophylact
vaccin
lifethreaten
diseas
dengu
ebola
fever
aid
hepat
c
continu
progress
polysaccharid
ps
base
materi
offer
signific
potenti
fight
virus
consid
sever
abovement
aspect
viru
filter
made
cellulos
cel
deriv
implement
past
twenti
year
captur
viral
pathogen
environment
water
blood
product
sampl
ps
micronanoparticl
particularli
chitosan
deriv
extens
test
viral
vaccin
formul
alli
immunolog
adjuv
antigen
carrier
properti
present
review
examin
contribut
psbase
chromatograph
adsorb
antivir
warfar
associ
filtrat
procedur
liquid
chromatographi
technolog
wide
use
reduc
viral
contamin
biologicalbiopharmaceut
product
monoclon
antibodi
mab
blood
product
also
becom
major
step
biosepar
scheme
recoverypurif
virus
viruslik
particl
view
largescal
product
highpur
viral
stock
need
manufactur
safer
vaccin
viral
vector
gene
therapi
search
improv
tool
viral
contamin
infect
chromatograph
adsorb
base
ps
agaros
ag
cel
essenti
dextran
lesser
extent
tabl
proven
materi
choic
viru
purif
viru
remov
recent
develop
involv
convent
pack
bed
membran
adsorb
ma
vast
major
viral
vaccin
manufactur
present
includ
wholecel
vaccin
virus
either
live
attenu
inactiv
viruslik
particl
vlp
subunit
vaccin
contain
specif
part
viru
immunogen
properti
exampl
attenu
vaccin
smallpox
polio
oral
vaccin
measl
mump
rubella
rotaviru
gastroenter
yellow
fever
inactiv
vaccin
includ
rabi
polio
hepat
influenza
vaccin
licens
vlp
vaccin
hepat
b
human
papillomaviru
hpv
hepat
e
infect
also
current
avail
furthermor
number
vlp
vaccin
clinic
develop
manufactur
wholecel
vaccin
base
initi
virus
grown
vivo
whole
anim
ovo
embryon
egg
move
toward
anim
cell
cultur
system
allow
viru
propag
vitro
chicken
embryo
fibroblast
cef
primari
cell
human
lungderiv
medic
research
council
diploid
cell
african
green
monkey
kidneyderiv
vero
madin
darbi
canin
kidney
mdck
cell
continu
cell
line
common
cell
substrat
current
use
vaccin
product
vlp
produc
varieti
cell
cultur
system
includ
microbi
bacteria
yeast
mainli
escherichia
coli
saccharomyc
cerevisia
insect
eg
high
cell
trichoplusiani
use
baculoviru
express
vector
system
mammalian
eg
chines
hamster
ovari
cho
cell
lesser
extentpl
cell
therefor
whole
virus
vlp
design
vaccin
formul
deriv
complex
media
contain
biolog
impur
cell
debri
host
cell
hc
deriv
contamin
eg
protein
dna
endotoxin
downstream
process
must
compli
strict
puriti
requir
detail
regulatori
guidelin
typic
downstream
product
process
viral
particl
involv
three
main
step
fig
initi
clarif
virusvlp
load
bulk
medium
ensur
remov
cell
debri
larg
aggreg
centrifug
micro
filtrat
techniqu
commonli
util
initi
step
clarif
follow
concentrationpurif
step
final
polish
step
make
extens
use
varieti
chromatographi
techniqu
particular
ion
exchang
affin
hydrophob
interact
size
exclus
chromatographi
endonucleas
eg
eventu
ad
clarifi
viru
broth
ensur
degrad
contamin
nucleic
acid
hc
dna
preconcentr
step
clarifi
viru
broth
final
concentr
purifi
viru
suspens
use
chromatographi
techniqu
also
frequent
includ
process
chromatographi
stage
larg
perform
use
psbase
pack
bed
ma
oper
posit
bindandelut
neg
flowthrough
mode
effici
chromatograph
purif
step
usual
assess
recoveri
yield
viru
recov
puriti
control
quantifi
viru
viral
product
remain
contamin
viral
particl
effort
made
achiev
best
tradeoff
two
paramet
data
publish
far
highli
variabl
refer
paramet
yield
vs
puriti
ratio
could
allow
easier
comparison
purif
perform
difficult
standard
common
recoveri
yield
rang
around
puriti
promin
paramet
compromis
frequent
tabl
gather
varieti
packedb
column
chromatographi
procedur
appli
viral
particl
purif
stationari
phase
consist
ag
essenti
separationpharmaciaag
ge
healthcar
chicago
ill
seph
celeg
jnc
corpor
tokyo
japan
gel
bead
modifi
fulfil
vari
separ
mode
ie
ion
exchang
size
exclus
affin
tabl
among
anion
exchang
ae
frequent
implement
viru
purif
past
decad
mainli
associ
chromatograph
step
exampl
virusvlp
purif
expand
bed
chromatographi
use
agbas
adsorb
also
mention
tabl
anionexchang
chromatographi
aec
involv
adsorpt
viral
particl
whose
surfac
neg
charg
nearneutr
ph
posit
charg
chromatograph
support
ie
strong
weak
anion
exchang
carri
posit
charg
function
group
quaternari
ammonium
q
diethylaminoethyl
group
deae
adsorb
viral
particl
usual
elut
high
salt
buffer
around
nacl
contribut
elut
via
charg
screen
studi
quot
tabl
aec
base
seph
anion
exchang
provid
high
puriti
base
sdspage
analysi
vlp
vaccin
candid
viral
vector
design
gene
deliveri
high
infecti
particl
yield
use
expandedb
adsorpt
chromatographi
ebac
agbas
anion
exchang
also
illustr
ebac
propos
initi
simplifi
downstream
purif
process
target
product
particulatecontain
biolog
feedstocksbi
combin
clarif
concentr
product
captur
chromatographi
singl
step
ebac
appli
success
initi
purif
adenovir
vector
hepat
b
core
antigen
hbcag
protein
crude
viru
suspens
q
deae
ag
ligand
respect
adenoviru
adv
base
vector
wide
use
vaccin
vector
infecti
bacteri
viral
diseas
cancer
ebac
unclarifi
cultur
bulk
supplement
benzonas
yield
recoveri
concentr
adenovir
vector
whose
puriti
compar
obtain
classic
densiti
gradient
ultracentrifug
method
hbcag
selfassembl
icosahedr
vlp
also
promis
applic
vaccin
platform
particular
therapeut
vaccin
chronic
hepat
b
recoveri
yield
hbcag
heattreat
unclarifi
e
coli
homogen
puriti
ratio
hbcag
content
total
protein
content
c
purif
factor
ratio
hbcag
puriti
ebac
eluat
feedstock
c
antigen
recov
hbcag
preserv
far
ebac
limit
commerci
develop
note
howev
aeebac
method
captur
influenza
contain
hemagglutinin
ha
vlp
tobacco
plant
cell
use
particularli
deae
ps
cel
ag
dextran
bead
inert
core
patent
philip
morri
product
sa
neuchatel
switzerland
sharehold
medicago
inc
canada
compani
develop
plantbas
technolog
produc
antivir
vaccin
cation
exchang
ce
chromatographi
cec
resin
retain
viral
particl
ionic
interact
neg
charg
function
group
stationari
phase
eg
sulfon
phosphat
group
posit
charg
amino
group
viral
surfac
protein
gener
weakli
acid
condit
sinc
howev
virus
includ
human
virus
isoelectr
point
sensit
low
ph
cec
seldom
appli
purif
viral
particl
isol
studi
kim
et
al
use
psbase
chromatographi
media
concern
purif
major
capsid
protein
hpv
type
selfassembl
vlp
see
review
papillomaviru
assembl
hpv
vlp
highli
immunogen
main
compon
manufactur
prophylact
vaccin
hpv
infect
major
risk
factor
develop
cervic
anogenit
cancer
cecbas
purif
process
ensur
recoveri
protein
remov
contamin
protein
note
c
elimin
precipit
prior
chromatographi
step
protein
puriti
increas
compar
cell
lysat
viral
clearanc
biopharmaceut
safeti
actual
investig
applic
field
cec
illustr
section
size
exclus
chromatographi
sec
exploit
larg
size
virus
nm
size
parvovirus
picornavirus
smallest
one
compar
cellular
medium
contamin
viral
particl
exclud
intern
pore
nonadsorb
pack
materi
column
migrat
faster
smaller
contamin
retain
matrix
pore
year
ago
dextranbas
adsorb
ge
healthcar
commonli
appli
sec
purif
varieti
virus
vlp
resin
vari
fraction
rang
recent
work
quot
tabl
also
make
use
dextranbas
resin
sec
often
associ
chromatographi
step
howev
agbas
media
frequent
use
like
aec
sec
success
appli
purif
gene
deliveri
vector
vlp
vaccin
use
pilotscal
evalu
manufactur
process
vaccin
candid
enteroviru
infect
chang
et
al
use
sec
downstream
purif
crude
bulk
deriv
infect
vero
cell
cultur
chromatograph
step
remov
protein
contamin
four
viral
stock
inconsist
viru
recoveri
yield
among
four
test
howev
addit
residu
dna
level
vaccin
bulk
compli
current
guidelin
human
vaccin
chemic
inactiv
purifi
virus
found
immunogen
anim
model
induc
strong
viru
neutral
antibodi
respons
mice
rabbit
late
wang
et
al
appli
process
ie
sec
preced
tangentialflow
ultrafiltr
uf
purif
cell
culturederiv
classic
swine
fever
viru
similarli
posit
result
term
viru
recoveri
puriti
infect
purif
procedur
exploit
complementar
sec
aec
ie
sec
effici
remov
smallsiz
impur
less
separ
viral
particl
larger
impur
genom
hc
dna
fragment
aec
abil
discrimin
neg
charg
speci
eg
virus
hc
dna
protein
act
phionic
strength
mobil
phase
elut
buffer
essenti
instanc
twostep
chromatograph
procedur
ie
sec
follow
aec
current
appli
polioviru
purif
routin
downstream
process
inactiv
polio
vaccin
kalbfuss
et
al
recent
bohua
et
al
follow
chromatograph
scheme
purifi
cell
culturederiv
iav
porcin
reproduct
respiratori
syndrom
viru
prrsv
respect
former
work
howev
aec
column
use
flowthrough
mode
remov
hc
dna
secpurifi
iav
concentr
dna
adsorb
q
seph
xl
stationari
phase
virus
collect
flow
purif
result
signific
reduct
total
protein
hc
dna
content
treat
viral
suspens
yet
insuffici
fulfil
current
puriti
standard
whole
viru
human
influenza
vaccin
szurgot
et
al
replac
sucros
densiti
gradient
ultracentrifug
sec
first
purif
step
adenovir
dodecahedron
vlp
insect
cell
lysat
improv
significantli
recoveri
yield
vlp
purif
complet
aec
use
synthet
q
adsorb
provid
basi
shorter
costeffect
fulli
chromatograph
twostep
procedur
eglon
et
al
report
product
highqual
adv
vector
suitabl
clinic
develop
combin
aec
sec
purif
benzonas
treatment
appli
chromatographi
obtain
better
puriti
aecsec
secaec
focus
singlestep
chromatograph
purif
hpv
vlp
via
cec
afc
see
kim
et
al
implement
twostep
purif
process
sec
follow
cec
hpv
vlp
purifi
way
immunogen
mice
purif
effect
recoveri
yield
low
ultracentrifug
yeast
lysat
use
first
purif
step
preced
sec
substitut
ultracentrifug
ammonium
sulfat
precipit
strongli
decreas
loss
vlp
cell
lysat
pretreat
condit
whole
process
ensur
recoveri
approxim
purifi
vlpform
protein
lower
obtain
later
use
singlestep
cec
anoth
mean
avoid
densiti
gradient
ultracentrifug
step
need
convent
cell
lysat
pretreat
produc
purifi
viral
particl
cell
cultur
supernat
strategi
follow
tomono
et
al
implement
ultracentrifugationfre
pure
chromatographybas
techniqu
purif
raav
appli
dual
cecaec
step
use
poli
ethersulfon
pe
base
follow
sec
dextranbas
superdex
led
highli
purifi
gene
deliveri
vector
countercurr
simul
move
bed
smb
technolog
implement
improv
perform
chromatograph
separ
downstream
process
biopharmaceut
product
replac
singlecolumn
discontinu
step
continu
multicolumn
process
date
biopharmaceut
target
smb
chromatographi
smbc
mainli
protein
mab
nevertheless
secsmbc
recent
appli
purif
cell
culturederiv
iav
human
adv
type
use
column
pack
seph
ff
resin
particularli
promis
result
obtain
nestola
et
al
twocolumn
setup
yield
higher
viru
recoveri
puriti
hc
dna
protein
clearanc
batch
singlecolumn
sec
process
amount
stationari
phase
studi
claim
increas
product
compar
batch
mode
key
featur
develop
continu
downstream
bioprocess
affin
chromatographi
afc
base
bioselect
adsorpt
compound
immobil
ligand
gener
bound
pack
materi
via
spacer
arm
adsorb
compound
elut
either
ph
andor
ionic
strength
shift
competit
displac
heparin
hep
wide
use
afc
ligand
protein
isol
purif
hep
structur
relat
heparan
sulfat
highli
sulfat
glycosaminoglycan
ubiquit
present
mammalian
cell
surfac
serv
receptor
viru
attach
entri
hc
henc
hep
bind
viral
particl
display
antivir
activ
solut
particular
hiv
hep
also
serv
afc
ligand
viral
target
approach
hepseph
afc
column
hep
coval
coupl
crosslink
ag
bead
appli
purif
whole
virus
cell
cultur
vlp
yeast
cultur
hep
afc
associ
uf
concentr
step
recov
prrsv
clarifi
cell
lysat
chromatographi
step
remov
protein
captur
virus
present
uf
retent
elut
two
differ
ionic
strength
prrsv
load
onto
column
could
recov
increas
puriti
respect
c
compar
retent
hep
afc
compar
cec
abil
purifi
vlpform
hpv
protein
howev
hep
afcpurifi
vlp
show
higher
immunogen
mice
cecpurifi
one
affin
ligand
camelid
antibodi
fragment
concanavalin
use
purifi
recombin
viral
vector
intend
cellular
gene
therapi
ie
antivir
object
sensu
lato
like
hep
cel
sulfat
semisynthet
product
welldocu
controversialantivir
activ
hiv
mimick
hep
affin
wide
rang
protein
pseudoaffin
pseudobiospecif
ligand
chromatographi
pafc
media
base
cel
sulfat
patent
kaketsuken
chemosero
therapeut
research
institut
kumamoto
japan
end
eighti
purifi
influenza
viru
japanes
enceph
viru
rabi
viru
sinc
cel
sulfat
bead
extens
implement
pack
materi
pafc
number
viru
purif
process
commerci
product
sulfat
jnc
corpor
produc
function
cel
bead
low
concentr
sulfat
ester
shown
effect
viru
purif
view
improv
product
process
vaccin
particular
flaviviru
infect
thu
cellufin
sulfat
chromatographi
polish
step
vero
cellderiv
japanes
enceph
viru
product
scheme
inactiv
japanes
enceph
vaccin
commerci
kaketsuken
kumamoto
japan
test
recent
year
phase
iii
clinic
trial
final
cellufin
sulfat
chromatograph
step
also
appli
purif
wholeviru
inactiv
yellow
fever
vaccin
candid
produc
vero
investig
perform
cellufin
sulfat
resin
captur
cef
cellderiv
mvabn
viru
particl
homogen
clarifi
suspens
provid
manufactur
liquidfrozen
sampl
beadbas
pafc
yield
overal
viru
recoveri
contamin
deplet
doubl
strand
ds
dna
recoveri
product
fraction
protein
recoveri
flowthrough
fraction
compar
sulfat
cel
scma
see
detail
section
immunogen
safeti
imvamun
wide
test
phase
refer
therein
recent
phase
ii
eg
clinic
trial
liquidfrozen
frequent
freezedri
formul
imvamun
test
howev
mention
addit
pafcbas
purif
step
vaccin
sampl
c
product
safe
effect
influenza
vaccin
either
eggbas
cellbas
major
goal
pharmaceut
industri
current
licens
influenza
vaccin
deriv
embryon
egg
cell
cultur
technolog
emerg
approach
influenza
vaccin
manufactur
mdck
lesser
extent
vero
main
cell
line
use
influenza
vaccin
product
work
kalbfuss
et
al
coupl
sephbas
sec
aec
flowthrough
mode
purifi
iav
propag
mdck
cell
detail
earlier
surprisingli
cellufin
sulfat
pafc
also
use
purifi
influenza
virus
design
vaccin
formul
allanto
fluid
deriv
fertil
egg
cell
cultur
media
column
pafc
cel
sulfat
ester
affin
medium
initi
patent
protect
purif
influenza
virus
allanto
fluid
recent
chromatograph
step
use
commerci
cellufin
sulfat
show
effici
decreas
total
amount
protein
sampl
egggrown
human
avian
influenza
virus
divers
iav
influenza
b
ibv
strain
mainli
egg
protein
elimin
sinc
protein
coelut
viral
particl
viral
origin
howev
r
issu
princip
relat
purif
cell
culturederiv
virus
twenti
year
ago
palach
et
al
solvay
pharmaceut
bv
weesp
netherland
produc
influenza
subunit
vaccin
mdck
cell
intact
virus
isol
cell
cultur
medium
cellufin
sulfat
pafc
process
inactiv
surfac
antigen
vaccin
test
clinic
trial
result
prepar
show
equival
safeti
effici
exist
eggbas
commerci
vaccin
cell
medimmun
patent
purif
method
mdck
cellgrown
influenza
virus
use
cellufin
sulfat
column
togeth
benzonas
treatment
remov
effici
mdck
cell
dna
clarifi
concentr
viru
harvest
result
cellbas
laiv
would
preclin
phase
develop
exampl
cellufin
sulfat
util
purifi
vero
cell
culturederiv
influenza
vaccin
given
et
al
associ
three
chromatograph
separ
mode
downstream
process
inactiv
iav
viru
vero
cell
pafc
preced
aec
flowthrough
mode
follow
sec
overal
scheme
result
high
recoveri
viral
ha
activ
effici
remov
contamin
dna
protein
hc
dna
mainli
remov
aecpafc
reduct
factor
respect
hc
protein
elimin
pafcsec
reduct
factor
c
chromatograph
step
total
protein
dna
content
final
product
ie
protein
pg
dna
per
normal
vaccin
dose
ha
compli
world
health
organ
recommend
inactiv
singl
strain
influenza
vaccin
apart
wholecel
vaccin
research
alphavax
produc
vrp
express
ha
neuraminidas
iav
like
cmvtarget
alphaviru
vrp
vrp
express
influenza
antigen
produc
vero
cell
effici
purifi
pafc
use
cellufin
sulfat
column
vaccin
test
immunogen
anim
particularli
swine
see
also
refer
therein
human
fact
human
clinic
trial
virusvector
influenza
vaccin
use
poxviru
adv
vector
immobil
metal
pseudo
affin
chromatographi
imac
essenti
protein
purif
techniqu
base
affin
transit
metal
ion
zn
cu
ni
co
toward
certain
amino
acid
residu
eg
histidin
cystein
see
refer
hydrophob
interact
chromatographi
hic
base
interact
chromatograph
support
function
moder
hydrophob
ligand
propyl
butyl
octyl
phenyl
group
hydrophob
region
adsorb
hic
mainli
oper
neg
flowthrough
mode
polish
step
purif
process
protein
antibodi
ensur
remov
product
relat
impur
aggreg
process
contamin
hc
protein
column
hic
agbas
resin
seph
use
viru
reduct
step
biomolecul
purif
process
detail
hereinaft
hic
occasion
appli
viru
purif
bindandelut
mode
use
column
pack
hydrophob
polymethacryl
bead
associ
phenyl
seph
bead
hic
q
aec
sp
cec
seph
bead
column
improv
flowthrough
purif
influenza
viru
clarifi
cell
cultur
supernat
improv
flowthrough
recoveri
virus
use
bead
increas
mean
size
big
bead
diamet
minim
extern
surfac
area
avail
viru
adsorpt
henc
process
patent
combin
sec
bind
chromatographi
oper
differ
mode
high
viru
recoveri
total
protein
remov
achiev
flowthrough
fraction
still
contain
residu
dna
viruss
contamin
wellidentifi
limit
neg
chromatographi
applic
viral
particl
purif
mix
mode
multimod
chromatographi
mmc
compound
interest
mobil
phase
interact
stationari
phase
materi
combin
bind
mode
includ
ion
exchang
hydrogen
bond
hydrophob
interact
mmc
method
exist
sinc
hydroxyapatit
chromatographi
combin
ce
metal
affin
although
new
idea
mmc
increasingli
develop
pharmaceuticalbiopharmaceut
applic
owe
new
gener
mixedmod
stationari
phase
better
understand
multimod
interact
particlebas
mmc
media
report
recent
year
base
silica
gel
implement
separ
purpos
howev
sever
bead
ag
support
recent
appli
purif
virus
vlp
neg
mode
q
inertlay
biotoolom
ltd
consett
uk
adsorb
consist
highli
crosslink
ag
bead
quaternari
ammonium
cation
glycidyltrimethylammonium
chlorid
gtmac
coat
inert
ligand
free
ag
layer
differ
thick
inert
shell
respect
way
core
ge
healthcar
particl
compos
ligandactiv
ag
core
inact
ag
shell
ligand
octylamin
hydrophob
posit
charg
materi
inert
shell
exclud
larg
molecul
nanoparticl
virus
vlp
smaller
impur
bind
intern
ligand
funnelshap
pore
core
fig
target
virusesvlp
collect
column
flow
thu
purif
step
combin
size
separ
sec
bind
chromatographi
iec
iechic
lee
et
al
investig
purif
hbv
vlp
hepat
b
core
antigen
particl
clarifi
e
coli
feedstock
neg
chromatographi
use
coreshel
q
adsorb
biotoolom
increas
thick
inert
shell
q
sepfast
inertshel
vs
inertlay
improv
recoveri
decreas
puriti
vlp
flowthrough
fraction
vlp
impur
hc
protein
exclud
largeshel
bead
better
compromis
recoveri
puriti
obtain
use
gtmaccation
ag
bead
graft
poli
oligo
ethyleneglycol
methacryl
noncrosslink
polym
chain
act
size
exclus
layer
chromatographi
shown
effect
purifi
differ
virus
first
iav
illustr
also
manufactur
applic
note
reovirus
adv
respiratori
syncyti
viru
rsv
reoviru
oncolyt
viru
potenti
applic
target
treatment
cancer
adv
wide
appli
vector
gene
deliveri
rsv
caus
sever
infect
lung
respiratori
tract
infant
develop
safe
effect
prophylact
vaccin
rsv
remain
challeng
context
mundl
et
al
purifi
liveattenu
rsv
vaccin
strain
fourstep
purif
process
center
chromatographi
chromatograph
step
preced
benzonas
treatment
clarif
follow
viru
concentr
use
ufdiafiltr
df
hollow
fiber
tangenti
flow
filtrat
mmc
found
highli
effici
remov
vero
hc
protein
dna
viruscontain
column
flow
purif
factor
respect
notic
reduct
viru
titer
test
vivo
rat
result
vaccin
display
immunogen
protect
rsv
challeng
typic
downstream
purif
process
viral
particl
whole
virus
vlpsfor
biomed
applic
includ
sever
chromatographi
unit
oper
separ
concentrationpurif
procedur
ufdf
variou
exampl
twostep
chromatographi
procedur
associ
sec
aec
cec
hic
viru
purif
alreadi
mention
way
base
mmc
frequent
coupl
anoth
chromatograph
step
purifi
whole
virus
vlp
sec
also
afc
particularli
aec
thu
capto
q
aec
associ
mmc
twostep
flowthrough
process
purifi
cellbas
influenza
virus
vaccin
manufactur
work
aec
column
captur
hc
dna
dnapurifi
flow
contain
virus
appli
onto
mmc
column
retain
hc
protein
hydrophob
compound
accord
applic
note
publish
ge
healthcar
run
two
chromatographi
column
seri
gave
similar
process
yield
ha
recoveri
puriti
run
column
separ
arrang
minim
handl
viru
suspens
like
improv
product
howev
weigel
et
al
tseng
et
al
use
two
column
separ
former
ad
benzonas
aec
flow
latter
propos
dnasefre
process
yield
ha
recoveri
protein
remov
dna
remov
two
column
overal
purif
process
includ
ufdf
step
chromatographi
ensur
ha
recoveri
protein
remov
dna
remov
refer
crude
viru
harvest
recent
howev
weigel
et
al
replac
mmc
flow
bindandelut
hic
purifi
iavibv
clarifiedconcentr
cell
cultur
broth
ie
use
hic
viru
captur
step
dnasefre
aec
flow
lose
advantag
flowthrough
mode
avoid
benzonas
treatment
process
yield
similarslightli
improv
viru
recoveri
purif
perform
compar
twostep
flowthrough
process
therefor
hic
found
effici
mmc
combin
bind
size
exclus
properti
concern
vlp
ge
healthcar
describ
purif
hpv
vlp
mmc
follow
capto
q
aec
posit
mode
hpv
vlp
consist
selfassembl
pentam
recombin
hpv
capsid
protein
express
insect
cell
infect
baculoviru
contain
protein
gene
vlp
present
clarifi
cell
lysat
collect
mmc
flow
next
provid
dithiothreitol
dtt
disassembl
vlp
protein
monom
protein
captur
aec
column
elut
stepwis
gradient
nacl
vlp
could
reassembl
remov
dtt
eluat
puriti
protein
ratio
protein
total
protein
recov
twostep
procedur
high
dna
endotoxin
remov
evalu
lagoutt
et
al
associ
mmc
superdex
sec
purif
process
vlpbase
influenza
vaccin
produc
e
coli
introduc
deterg
extract
step
two
chromatograph
step
remov
residu
e
coli
protein
contamin
mmc
flowthrough
process
effici
discuss
term
vlp
puriti
recoveri
yield
mmc
result
increas
vlp
puriti
compar
clarifi
bacteri
lysat
recoveri
yield
vlp
puriti
reach
recoveri
yield
deterg
extract
sec
polish
remov
contamin
dna
endotoxin
may
packag
cellassembl
vlp
assess
nevertheless
qualiti
monitor
vlpbase
vaccin
bulk
includ
control
residu
dna
protein
endotoxin
content
addit
determin
protein
puriti
recent
exampl
vlp
purif
benzonasetr
cell
cultur
supernat
associ
mmc
afc
hep
afc
step
use
separ
vlp
extracellular
vesicl
exosom
microvesicl
present
mmc
flow
mmc
flowthrough
particl
recov
afc
elut
peak
particl
mixtur
enrich
vlp
illustr
mani
conclus
result
obtain
use
psbase
stationari
phase
convent
packedb
column
chromatographi
prove
effici
captur
viral
particl
howev
technolog
face
mani
technic
limit
among
limit
access
ligand
within
resin
hinder
pore
diffus
viral
particl
fig
limit
flow
rate
due
high
column
back
pressur
lead
suboptim
product
rate
altern
chromatographi
media
ie
monolith
column
ma
develop
overcom
technic
limit
monolith
continu
stationari
phase
cast
singl
block
insert
chromatographi
hous
monolith
made
inorgan
polym
base
silica
synthet
organ
polym
polyacrylamid
polymethacryl
membran
chromatographi
rel
new
immatur
biosepar
technolog
base
integr
membran
filtrat
liquid
chromatographi
singlestag
oper
ma
repres
fastgrow
segment
biopharmaceut
manufactur
market
base
micropor
polym
membran
gener
use
multipl
layer
membran
materi
includ
synthet
organ
polym
pe
polyvinyliden
fluorid
pvdf
polypropylen
pp
natur
polym
essenti
regener
cel
monolith
membran
media
function
ligand
use
convent
chromatographi
resin
eg
weak
deae
strong
q
anion
exchang
owe
porou
architectur
adsorpt
media
mass
transfer
adsorb
bind
site
govern
predominantli
convect
rather
diffus
fig
dynam
bind
capac
therefor
larg
independ
mobil
phase
flow
rate
process
time
greatli
reduc
monolith
column
ma
shown
promis
viru
captur
effici
exampl
quaternari
aminefunction
polymethacryl
monolith
cim
convect
interact
media
qa
bia
separ
villach
austria
extens
appli
viru
vlp
purif
recent
year
monolith
base
ps
particular
ag
agchitosan
composit
agchitosanhybrid
implement
afc
column
purif
biolog
target
refer
viral
contamin
work
fernand
et
al
except
success
bound
elut
chitosanpva
monolith
function
q
ligand
convers
implement
ma
chromatographi
tool
captur
viral
particl
welldocu
past
ten
year
tabl
summar
main
characterist
control
viru
purif
perform
ma
compar
packedb
resin
impli
gain
product
viru
product
rate
yield
reduct
process
time
also
potenti
loss
viru
puriti
excess
level
dna
protein
impur
replac
column
therefor
number
viru
purif
process
associ
two
chromatograph
process
complementari
tabl
focus
celbas
adsorpt
membran
wide
test
viru
purif
togeth
pe
membranebas
adsorb
work
quot
tabl
use
flat
sheet
sart
membran
sartoriu
ag
germani
ie
crosslink
regener
cel
membran
larg
pore
contain
homogen
graft
bind
site
mainli
includ
strong
weak
anion
exchang
also
affin
ligand
pseudoaffin
sulfat
cel
membran
also
increasingli
develop
patent
protect
eg
studi
keep
search
virusvlp
purif
method
allow
larg
scale
product
clinicalgrad
human
vaccin
eg
influenza
viral
vector
eg
recombin
adv
baculovirus
gene
deliveri
mammalian
cell
thoroughli
support
promot
manufactur
viru
purif
process
make
use
commerci
sart
ma
develop
year
ago
particular
attent
ae
ma
agreement
trend
gener
result
work
underlin
ma
gave
improv
viru
yield
andor
product
compar
convent
pack
bead
strong
membran
ion
exchang
q
effici
weak
one
c
whatev
chromatographi
separ
mode
ion
exchang
affin
purif
effici
sart
ma
quasisystemat
affect
presenc
hc
dna
elut
product
fraction
level
dna
impur
exceed
current
regulatori
requir
clinic
applic
instanc
hc
dna
recov
complet
ha
ie
iav
enrich
product
fraction
elut
sart
q
imac
treatment
best
adsorptionelut
buffer
condit
amount
hc
dna
iav
desorb
reduc
remain
equal
untreat
viru
pool
q
pall
corpor
port
washington
ny
usa
pesbas
strong
ae
membran
appear
promis
sart
q
baculoviru
purif
yield
lower
level
hc
dna
protein
viral
eluat
sart
q
membran
also
less
effici
qa
monolith
adv
vector
purif
residu
dna
impur
elimin
howev
amount
contamin
dna
could
lower
nucleas
pretreat
appli
studi
suggest
other
andor
combin
chromatograph
step
thu
vicent
et
al
use
sec
resin
polish
pool
rotaviruslik
particl
captur
sart
aec
contamin
dna
elimin
polish
step
howev
addit
aec
step
necessari
complet
dna
remov
yield
dnamg
vlp
final
product
sart
imac
found
insuffici
reduc
level
dna
contamin
coelut
adv
particl
packedb
aec
treatment
adv
pool
benzonas
second
chromatograph
step
remain
necessari
lower
significantli
dna
concentr
final
pool
way
wolff
et
al
associ
heparinma
pafc
sart
q
aec
reduc
dna
contamin
vaccinia
viru
eluat
level
doubl
strand
dna
dsdna
reduc
pafc
total
dsdna
present
start
viral
materi
deplet
aec
howev
still
suffici
evad
nucleas
treatment
submit
pafc
viru
eluat
column
hic
led
similar
conclus
recent
nestola
et
al
propos
flowthrough
purif
process
retroviru
vlp
sart
stic
salt
toler
interact
chromatographi
ae
mmc
pack
bead
column
connect
seri
chromatographi
train
preced
ufdf
benzonasetr
vlp
bulk
reduct
dna
content
achiev
togeth
reduct
hc
protein
content
vlp
recoveri
howev
latest
studi
perform
use
sulfat
cel
ma
pseudoaffin
ma
made
regener
cel
crosslink
sulfat
allow
like
commerci
sart
ma
higher
volumetr
flow
rate
adsorpt
scma
led
enhanc
viru
product
compar
convent
bead
adsorb
particular
cellufin
sulfat
purif
perform
scma
also
compar
afc
ionexchang
sart
ma
term
contamin
deplet
contamin
remov
scma
equival
total
protein
slightli
higher
dna
obtain
use
heparinfunction
also
scma
ensur
significantli
improv
dna
deplet
compar
ce
ae
exchang
ma
howev
dna
elimin
still
remain
incomplet
even
ad
second
chromatographi
step
purif
process
use
statist
optim
methodolog
ie
design
experi
doe
carvalho
et
al
recent
report
better
vlp
yield
total
protein
remov
scma
sart
aeccec
ma
dna
level
sart
scma
product
fraction
low
limit
detect
quantif
method
use
howev
cell
cultur
treat
benzonas
vlp
harvest
carvalho
et
al
also
assess
purif
whole
iav
particl
preliminari
nucleas
treatment
viru
yield
reach
residu
dna
level
ng
ha
remain
well
regulatori
recommend
influenza
vaccin
ie
ng
dnados
parenter
administr
know
normal
vaccin
dose
contain
ha
per
iav
strain
parallel
studi
group
appli
doe
method
specif
optim
iav
purif
use
industri
scma
prototyp
obtain
compar
result
regard
viru
yield
remov
hcrelat
dna
protein
impur
display
higher
product
commerci
sulfat
resin
weigel
et
al
test
twostep
membran
chromatographi
approach
improv
purif
level
iav
prepar
avoid
nucleas
treatment
contrari
twostep
packedb
chromatographi
process
report
previous
see
section
sart
stic
aec
oper
flowthrough
mode
polish
step
remov
residu
dna
scma
elut
product
arrang
show
higher
purif
effici
former
mabas
process
associ
scma
sart
q
aec
oper
bindandelut
mode
whose
purif
perform
imped
coelut
viru
particl
dna
impur
sart
q
thu
purifi
iav
prepar
viru
yield
contain
ng
dna
per
monoval
vaccin
dose
ha
compli
contamin
limit
recommend
regulatori
author
socal
steric
exclus
chromatographi
sex
larges
target
speci
protein
virus
adsorb
surfac
hydrophil
nonreact
membran
mutual
steric
exclus
poli
ethylen
glycol
lee
et
al
illustr
separ
effici
techniqu
purifi
immunoglobulin
g
igg
bacteriophag
use
hydroxylsubstitut
polymethacryl
monolith
hydrophil
surfac
sex
implement
recent
purif
cell
culturederiv
iav
use
simpl
regener
cel
pore
size
membran
filter
altern
monolith
high
viru
recoveri
reach
appli
nucleas
treatment
prior
chromatographi
hc
ds
dna
deplet
high
lowest
residu
dna
level
product
eluat
c
ha
viral
clearanc
applic
viral
particl
product
interest
impur
must
reduc
level
accept
human
use
viru
elimin
inactivationremov
critic
number
biopharmaceut
clinic
applic
valid
viru
clearanc
see
comprehens
overview
essenti
manufactur
biopharmaceut
prerequisit
clinic
trial
commerci
launch
bloodand
mammalian
cell
culturederiv
therapeut
protein
ig
mab
viru
inactiv
technolog
includ
physic
eg
heat
applic
ultravioletand
gamma
irradi
chemic
method
eg
low
ph
solventdeterg
treatment
viru
remov
ensur
combin
filtrat
chromatographi
step
fig
quantit
assess
viru
reduct
capac
unit
oper
eg
chromatographi
manufactur
process
perform
viral
clearanc
studi
submit
number
regulatori
consider
experi
product
intermedi
artifici
contamin
spike
select
virus
gener
repres
potenti
viral
contamin
sourc
materi
tabl
viru
reduct
capac
test
step
express
log
reduct
valu
lrv
ie
log
ratio
viral
load
spike
product
intermedi
recov
product
process
step
yield
lrv
consid
effect
viral
clearanc
alli
chemic
inactiv
nanofiltr
nf
main
process
step
dedic
viral
remov
manufactur
perform
celbas
virusretent
filter
typic
filter
asahi
kasei
medic
tokyo
japan
downstream
purif
process
biopharmaceut
detail
recent
review
instanc
purif
process
recombin
coagul
factor
viii
bloodclot
protein
whose
defici
associ
hemophilia
patent
octapharma
ag
lachen
switzerland
includ
solventdeterg
sd
treatment
planova
nf
five
chromatographi
step
use
psbase
stationari
phase
ie
mmc
capto
mmc
cec
sp
seph
ff
afc
viiiselect
capto
matrix
factor
viiiselect
ligand
aec
q
seph
ff
sec
superdex
howev
sd
treatment
nf
evalu
viral
clearanc
nevertheless
chromatographi
step
provid
signific
contribut
overal
viru
remov
effici
purif
process
welldocu
past
year
earli
studi
see
detail
review
chromatographi
plasma
product
manufactur
iec
process
associ
weak
aec
deae
seph
ff
cec
carboxymethyl
cm
seph
ff
test
capac
remov
polioviru
type
canin
parvoviru
cpv
hepat
viru
human
albumin
purif
latter
process
involv
addit
sec
step
use
sephacryl
column
yield
cumul
lrv
across
three
chromatograph
step
work
well
newer
studi
cite
cec
column
oper
bindandelut
mode
desir
product
retain
cec
resin
viral
particl
remain
flow
aec
column
oper
flowthrough
mode
ie
neg
charg
viral
impur
captur
adsorb
mainli
electrostat
interact
desir
product
remain
flow
recent
cec
column
pack
cm
seph
ff
use
success
clear
virus
ig
sampl
spike
envelop
virus
dengu
viru
herp
simplex
viru
type
sindbi
viru
sinv
viru
remov
antibodi
solut
also
achiev
use
cec
column
pack
bead
capto
sp
seph
ff
resin
latter
work
howev
model
retrovirus
xenotrop
mlv
xmlv
bound
tightli
resin
remain
attach
antibodi
elut
salt
gradient
despit
posit
result
publish
year
ago
cec
consid
less
robust
aec
remov
viral
contamin
therapeut
protein
prepar
aec
robust
valid
sever
studi
aec
column
pack
strong
ae
resin
q
seph
ff
work
mab
sampl
spike
model
virus
xmlv
simian
viru
minut
viru
mice
mvm
viral
clearanc
assess
vari
oper
condit
includ
obvious
ph
conduct
salt
concentr
mobil
phase
also
column
load
densiti
mg
mabml
resin
impur
level
aggreg
mab
hc
dna
protein
mab
feedstock
els
pool
criteria
passthrough
fraction
viral
clearanc
effici
chromatographi
step
highlight
lrv
greater
proper
oper
condit
q
seph
ff
chromatographi
also
shown
remov
effect
porcin
circoviru
type
adventiti
contamin
oral
vaccin
rotaviru
gastroenter
children
smallsiz
highli
resist
physic
inactiv
procedur
lrv
valu
achiev
nf
planova
filter
ineffici
moder
pore
size
filter
howev
column
load
consist
viral
suspens
buffer
biopharmaceut
contamin
ad
virusspik
product
intermedi
use
determin
viru
reduct
capac
differ
process
step
order
assess
viral
safeti
manufactur
biopharmaceut
alreadi
state
aec
consid
effect
viru
reduct
step
manufactur
process
contrari
nf
addit
alreadi
mention
studi
wing
et
al
anoth
recent
exampl
given
nowak
et
al
evalu
viral
safeti
human
prothrombin
complex
pn
csl
behr
king
prussia
pa
usa
report
effici
remov
test
virus
serial
filtrat
planova
filter
wherea
column
aec
deae
resin
crosslink
dextran
matrix
deae
group
attach
glucos
unit
test
prion
remov
afc
wellestablish
primari
isol
step
purif
process
biopharmaceut
particular
antibodi
product
interest
select
adsorb
matriximmobil
ligand
noninteract
impur
remain
flow
captur
step
may
achiev
effici
viral
clearanc
provid
contrari
hepbas
ligand
use
viru
purif
see
section
ligand
adsorb
virus
adsorb
virus
elut
product
proper
oper
condit
therefor
mani
manufactur
process
biopharmaceut
eg
antihemophil
factor
incorpor
afc
step
contribut
overal
viru
remov
effici
addit
dedic
nf
step
tabl
psbase
afc
resin
evalu
viral
clearanc
consist
ag
seph
matrix
antibodi
bind
protein
antibodyantibodi
fragment
attach
staphylococc
protein
streptococc
protein
g
common
affin
ligand
antibodi
captur
protein
surfac
protein
gramposit
bacterium
staphylococcu
aureu
high
affin
ig
variou
speci
particular
igg
commerci
mab
process
incorpor
protein
afc
step
antibodi
purif
protein
media
specif
captur
antibodi
may
bind
modest
level
adventitiousendogen
virus
via
nonspecif
interact
virus
media
resin
backbon
protein
ligand
mab
product
henc
protein
media
frequent
subject
viral
clearanc
valid
studi
yield
low
highli
variabl
lrv
valu
eg
xmlv
depend
mab
product
case
ps
materi
base
crosslink
ag
matrix
coupl
natur
staphylococc
protein
protein
seph
ff
alkalistabil
recombin
protein
mabselect
ge
healthcar
two
studi
report
accept
c
moder
lrv
level
endogen
retrovir
particl
present
antibodi
feedstock
cell
cultur
harvest
lrv
remain
stabl
sever
hundr
cycl
purificationclean
robust
viral
clearanc
respect
media
age
confirm
use
multispik
xmlv
mvm
feedstock
recent
work
bach
et
al
investig
mechan
xmlv
clearanc
mabselect
sure
resin
show
low
clearanc
due
mainli
viru
bind
elut
mab
notic
interact
xmlv
ligand
ag
matrix
sinc
viru
alon
mab
ad
column
load
retain
neither
protein
resin
underivat
seph
lrv
protein
afc
use
mabselect
sure
resin
also
use
captur
step
manufactur
process
recombin
factor
ix
fc
fusion
protein
rfixfc
biogen
cambridg
mass
sobi
ab
stockholm
sweden
approv
bloodclot
medicin
haemophilia
b
afc
follow
two
aec
step
final
nf
test
clearanc
four
model
virus
addit
planova
filtrat
afc
q
seph
ff
aec
contribut
significantli
viru
remov
lrv
rang
mvm
xmlv
afc
tabl
mvm
xmlv
reoviru
type
aec
protein
g
extract
group
c
g
streptococci
though
wide
use
antibodi
purif
process
protein
g
chromatographi
resin
scarc
evalu
viral
clearanc
exampl
given
robert
investig
viru
elimin
purif
immunoglubulin
produc
human
hybridoma
celllin
purif
process
involv
three
sequenti
column
chromatographi
step
use
psbase
resin
ie
protein
g
afc
protein
g
seph
cec
sp
seph
ff
sec
superdex
complet
two
specif
viru
elimin
step
sd
treatment
nf
protein
g
afc
prove
effect
elimin
envelop
sinv
nonenvelop
model
virus
show
even
better
remov
effici
nf
use
pvdf
filter
smallsiz
howev
igg
acid
elut
probabl
contribut
high
lrv
valu
obtain
envelop
phsensit
virus
viru
remov
cec
lower
sec
limit
impact
viral
clearanc
addit
wealth
antihemophil
fviii
product
current
avail
market
rang
earli
plasmaderiv
fourthgener
recombin
product
mabbas
immunoaffin
chromatographi
iac
key
purif
step
manufactur
process
commerci
fviii
compound
chemic
inactiv
nf
devot
viral
clearanc
like
mab
product
nevertheless
studi
investig
viru
remov
effici
iac
step
seph
matrix
antifviii
mab
ligand
use
adsorb
murin
mab
igg
coupl
nhydroxysuccinimid
nh
activ
seph
seph
recombinantli
produc
antifviii
mab
coupl
cyanogen
bromid
cnbr
activ
seph
ff
mab
iac
associ
sec
superdex
sd
treatment
nf
assur
viral
safeti
bdomain
delet
recombin
factor
viii
bddrfviii
wyeth
ltd
pfizer
new
york
ny
usa
produc
cho
cell
second
gener
product
humanderiv
protein
ad
final
formul
reduc
risk
viral
transmiss
mabseph
column
poorli
retain
model
virus
lrv
rang
pv
infecti
bovin
rhinotrach
viru
bovin
herpesviru
manufactur
process
includ
three
chromatographi
step
use
sephbas
resin
cec
aec
hic
test
viral
clearanc
expect
provid
addit
viru
remov
note
howev
antifviii
mous
mab
ligand
replac
later
synthet
peptid
avoid
use
animalderiv
materi
manufactur
process
refacto
lead
thirdgener
product
af
albumin
free
pfizer
afc
step
also
significantli
contribut
viral
clearanc
capac
modifi
process
tabl
product
process
plasmaderiv
bio
product
laboratori
elstre
uk
iac
column
load
sd
treat
fviii
intermedi
eluat
appli
aec
column
addit
purif
similar
method
use
make
hemofil
baxter
deerfield
ill
usa
two
product
differ
plasma
sourc
robert
evalu
effect
iac
elimin
virus
manufactur
process
iac
step
prove
effect
elimin
model
virus
lrv
sinv
bovin
parvoviru
bpv
howev
clearanc
contrari
sinv
bpv
poorli
affect
sd
presenc
could
attribut
part
chromatographi
step
turoctocog
alfa
novo
nordisk
bagsvaerd
denmark
bdomain
truncat
recombin
fviii
molecul
manufactur
cho
cell
use
human
animalderiv
materi
minim
viral
risk
thirdgener
rfviii
product
manufactur
process
includ
sever
success
chromatographi
step
captur
fviii
product
purif
whose
viru
clearanc
capac
evalu
ellgaard
et
al
particular
mmc
capto
mmc
resin
use
fviii
captur
antifviii
iac
use
mab
coupl
seph
use
purif
step
initi
captur
step
mmc
resin
adsorb
fviii
wash
deterg
viru
inactiv
significantli
contribut
result
viral
clearanc
howev
antifviii
iac
ensur
effici
viru
elimin
detergentfre
mmc
eluat
lrv
rang
mvm
ecotrop
mlv
tabl
recombin
protein
ligand
deriv
heavychain
antibodi
found
camelida
develop
trademark
own
thermo
fisher
scientif
waltham
mass
usa
ensur
afc
primari
captur
step
purif
process
therapeut
protein
includ
nonantibodi
target
equival
protein
mab
purif
incorpor
proprietari
ligand
technolog
viiiselect
resin
design
purif
factor
viii
compound
provid
good
viral
clearanc
xmlv
mvm
lrv
improv
hc
dna
protein
clearanc
cell
cultur
sampl
contain
factor
viii
compound
togeth
chromatographi
step
aec
hic
viiiselect
afc
purif
step
next
includ
manufactur
process
recombin
factor
viii
fc
fusion
protein
rfviiifc
sobi
biogen
longact
coagul
factor
approv
treatment
hemophilia
process
also
compris
deterg
inactiv
nf
ensur
viral
clearanc
contrari
wing
et
al
assess
pathogen
safeti
purif
process
viru
remov
studi
involv
afc
aec
step
demonstr
signific
contribut
afc
much
lesser
extent
aec
viral
clearanc
overal
process
even
though
nf
planova
filter
achiev
substanti
remov
model
virus
tabl
imac
hic
seldom
appli
purif
viralsubvir
particl
vlp
see
section
respect
imac
also
use
occasion
purifi
plasma
coagul
factor
factor
viii
particularli
factor
ix
robert
assess
viru
elimin
effici
chromatograph
process
manufactur
bio
product
laboratori
human
plasmaderiv
concentr
coagul
factor
ix
imac
perform
use
coppercharg
chelat
seph
ff
column
substanti
viru
remov
demonstr
virus
test
sinv
vaccinia
viru
independ
sd
presenc
includ
envelop
sinv
suscept
sd
treatment
mention
last
section
hic
column
chromatographi
use
hydrophob
seph
bead
involv
purif
scheme
plasma
coagul
factor
butyl
seph
hic
show
abil
clear
smallsiz
retain
nf
nonenvelop
resist
sd
treatment
mvm
mvmspike
xyntharefacto
af
sampl
octyl
seph
hic
test
viral
clearanc
manufactur
process
eloctaeloct
nevertheless
hic
consid
time
viru
reduct
step
protein
manufactur
butyl
seph
hic
second
three
chromatograph
step
afc
use
cellufin
sulfat
tandem
aeccec
use
qsp
seph
purif
process
recombin
bone
morphogenet
protein
dibotermin
alfa
activ
ingredi
bone
regener
formul
phenyl
seph
hic
second
three
success
viru
reduct
step
follow
pasteur
preced
filtrat
planova
filter
manufactur
process
human
esteras
inhibitor
plasmaderiv
product
studi
viral
clearanc
effici
differ
step
assess
spike
studi
use
panel
model
virus
viru
reduct
factor
hic
compar
frequent
use
viru
reduct
step
manufactur
process
turoctogog
alfa
purif
step
antifviii
iac
section
preced
product
captur
step
mmc
use
capto
mmc
resin
contain
particular
neg
charg
carboxyl
hydrophob
phenyl
group
thu
combin
weak
cec
hic
ellgaard
et
al
evalu
viru
clearanc
capac
captur
step
virus
elimin
column
flow
sinc
viral
clearanc
evalu
wash
resin
deterg
inactiv
virus
coadsorb
rfviii
significantli
contribut
result
viral
clearanc
data
concern
particularli
envelop
model
virus
clear
complet
combin
sec
aec
hic
mmc
oper
neg
mode
shown
effect
purifi
differ
virus
recov
column
flow
smallers
impur
retain
column
pack
see
section
mixedmod
resin
capto
adher
whose
ligand
also
contain
posit
charg
quaternari
amin
hydrophob
phenyl
hydrogenbond
hydroxi
group
devoid
size
exclus
layer
shown
promis
abil
retain
virus
suitabl
oper
condit
even
presenc
mab
product
process
impur
zhao
et
al
exploit
properti
introduc
capto
adher
mmc
step
multistep
chromatographi
purif
process
vlp
produc
insect
cell
follow
neg
mmc
capto
adherebas
aechic
step
may
also
contribut
viral
clearanc
remov
adventiti
virus
product
stream
downstream
purif
process
mab
biopharmaceut
recent
studi
brown
et
al
investig
bind
mechan
model
viru
surrog
ie
bacteriophag
display
differ
surfac
charg
characterist
hydrophob
capto
adher
resin
first
compar
effici
mmc
resin
pure
anion
capto
q
hydrophob
capto
phenyl
sephbas
resin
remov
phage
spike
buffer
vari
ph
salt
concentr
hydrophob
neg
charg
phage
adsorb
capto
adher
synergist
bind
quaternari
amin
phenyl
group
yield
better
phage
remov
effici
mmc
resin
lrv
test
buffer
condit
compar
singl
mode
one
howev
presenc
inprocess
impur
spike
mab
pool
affect
viru
remov
perform
multimod
resin
capto
adher
mmc
step
contributor
viral
clearanc
remain
implement
practic
downstream
purif
process
mab
biomolecul
intend
human
use
membran
chromatographi
devic
particular
commerci
aec
sart
q
pafc
scma
ma
shown
efficaci
captur
viral
particl
see
section
oper
bindandelut
mode
wide
implement
purifi
virus
vlp
complex
cultur
media
tabl
sinc
emerg
downstream
process
technolog
biopharmaceut
ma
also
frequent
use
flowthrough
mode
remov
trace
impur
includ
viral
contamin
product
stream
ie
polish
applic
field
clearanc
data
refer
hc
protein
dna
endotoxin
howev
work
publish
last
year
investig
viru
remov
q
membranebas
polish
step
antibodi
purif
concern
celbas
ma
first
viral
clearanc
experi
conduct
commerci
sart
q
membran
format
flowthrough
mode
show
moderatetolow
capac
q
membran
remov
xmlv
purifi
hightit
igg
load
lrv
decreas
increas
antibodi
load
sart
q
membran
oper
spiral
wind
format
membran
roll
core
form
cylind
area
test
zhou
et
al
viral
clearanc
antibodi
feed
stock
spike
model
viral
particl
differ
size
mvm
mlv
pseudorabi
viru
capsul
display
effici
remov
virus
lrv
trace
amount
processrel
impur
vari
process
capac
ie
mass
antibodi
process
per
unit
area
membran
later
zhou
et
al
detail
influenc
sever
oper
paramet
viral
clearanc
power
syring
filtertyp
sart
q
capsul
stack
membran
configur
vari
membran
area
show
particular
remov
effici
mvm
decreas
decreas
ph
increas
conduct
salt
concentr
virusspik
mab
feed
neg
effect
high
salt
concentr
screen
electrostat
interact
posit
charg
quaternari
ammoniumbas
ligand
neg
charg
impur
bind
capac
q
product
welldocu
refer
particular
convent
q
resin
overal
purif
process
mab
recombin
protein
howev
final
flowthrough
aecbas
polish
usual
preced
chromatograph
step
bindandelut
mode
eg
afc
protein
cec
elut
bound
materi
gener
high
salt
eluat
contain
target
product
trace
impur
feed
stream
dilut
prior
flowthrough
polish
therefor
necessari
drawback
q
ligand
led
develop
ma
function
altern
ae
ligand
show
extend
salt
toler
shown
primarysecondari
aminebas
ligand
display
high
abil
bind
neg
charg
speci
high
salt
concentr
owe
secondari
hydrogen
bond
interact
use
regener
cel
disc
base
membran
materi
riordan
et
al
test
variou
aminecontain
ligand
viru
remov
high
salt
challeng
viru
suspens
four
altern
ligand
includ
polyc
polyhexamethylen
biguanid
polyethyleneimin
achiev
lrv
bacteriophag
microvirida
mm
nacl
compar
lrv
commerci
mustang
q
membran
author
conclud
viru
remov
effici
cation
depend
net
posit
charg
ligand
molecular
structur
ligand
densiti
membran
use
surfaceiniti
atom
transfer
radic
polymer
atrp
bhut
et
al
graft
polyelectrolyt
q
chain
poli
methacryloyloxi
ethyl
trimethylammonium
chlorid
surfac
regener
cel
macropor
membran
produc
strong
ae
membran
variabl
polym
chain
graft
densiti
yield
ma
high
proteinbind
capac
viru
clearanc
perform
qbase
ma
evalu
use
mvm
spike
load
buffer
lrv
increas
degre
polym
graft
ie
polym
chain
densiti
reach
valu
given
mvm
load
howev
viru
clearanc
experi
perform
proteinfre
low
conduct
buffer
recent
develop
sart
stic
pa
use
polyallylamin
ligand
polyc
multipl
primari
amin
pa
group
improv
adsorpt
perform
high
salt
concentr
sart
stic
oper
flowthrough
mode
includ
purif
scheme
virus
vlp
remov
dna
protein
impur
viral
prepar
see
tabl
sart
stic
display
significantli
higher
viru
bind
capac
sart
q
presenc
mm
nacl
mscm
conduct
achiev
lrv
mvm
compar
q
membran
also
viru
captur
assay
carri
simpl
buffer
provid
variou
salt
amount
result
experi
assess
viral
clearanc
effici
sart
stic
process
publish
far
effici
viru
remov
q
ma
sartobind
mustang
differ
buffer
conductivitiessalt
concentr
also
compar
unfavour
emd
millipor
billerica
usa
anoth
commerci
avail
salttoler
consist
polyethylen
micropor
membran
coat
chemic
crosslink
hydrogel
allylamin
polym
chromasorb
adsorb
actual
display
higher
resist
salt
concentr
q
membran
ensur
robust
viru
retent
mvmspike
mab
feed
high
conduct
contrari
q
product
weaver
et
al
compar
perform
mvm
clearanc
three
commerci
ae
ma
rang
feed
condit
includ
absenc
presenc
hc
dnaprotein
impur
mab
reduct
mvm
remov
q
membran
high
salt
concentr
low
ph
confirm
toler
primari
aminebas
chromasorb
adsorb
ionic
strengthconduct
feed
solut
howev
chromasorb
capac
bind
mvm
sever
compromis
presenc
ion
capabl
form
hydrogen
bond
primari
amin
group
hydrogen
phosphat
ion
furthermor
primari
aminebas
chromasorb
show
lower
mab
recoveri
ie
higher
mab
bind
q
membran
chromatographi
current
remain
basic
tool
manufactur
biopharmaceut
particularli
downstream
purif
process
despit
increas
interest
nonchromatograph
techniqu
preval
reflect
number
recent
review
cover
instanc
wellestablish
afc
fast
develop
mmc
emerg
materi
includ
afc
mmc
ligand
cellulosebas
iec
media
els
continu
chromatographi
industri
viewpoint
consid
time
cours
publish
patentspat
applic
chromatographi
techniqu
last
twenti
year
fig
column
chromatographi
sensu
lato
remain
domin
concern
research
develop
field
far
format
chromatographi
monolith
membran
expand
bed
continu
chromatographi
particular
smbc
restrict
innov
impli
virus
column
process
still
domin
associ
emerg
ma
fig
affin
ionexchang
main
chromatographi
mode
publish
patent
associ
chromatographi
process
virus
fig
present
review
highlight
major
part
play
chromatographi
step
use
commerci
avail
psbase
chromatographi
media
ongo
purif
process
viral
particl
wholecel
virus
vlp
design
vaccin
formul
druggen
deliveri
vector
psbase
adsorb
also
current
implement
chromatograph
reduct
viral
contamin
biopharmaceut
product
perspect
psbase
chromatographi
materi
background
technolog
develop
r
effort
still
focu
celand
agbas
particul
adsorb
technolog
innov
also
concern
dextrancontain
resin
jnc
corpor
develop
porou
cel
particl
function
sulfat
ps
cel
dextran
pullulan
design
influenza
viru
purif
ps
sulfat
cel
dextran
pullulan
bind
cel
bead
viru
purif
perform
new
pafc
adsorb
compar
commerci
sulfat
see
section
sulfat
group
introduc
cel
particl
via
sulfat
esterif
treatment
show
higher
iav
adsorpt
capac
alli
reduc
adsorpt
capabl
nucleic
acid
contamin
commerci
chromatographi
medium
max
dexsvir
use
dextran
sulfat
polym
ligand
academ
studi
illustr
potenti
new
pafc
resin
viru
vlp
captur
purif
publish
far
manufactur
method
monolith
structur
made
esterifi
cel
patent
year
ago
applic
purif
bioprocess
still
lack
celbas
ma
consist
nonwoven
electrospun
cel
nanofib
function
deae
group
aec
develop
fibroselect
puridifi
ltd
stevenag
uk
part
ge
healthcar
display
higher
dynam
bind
capac
bovin
serum
albumin
model
protein
protein
product
membran
test
smb
system
ma
might
use
viral
vaccin
isol
shown
recent
viral
vector
varieti
new
ligand
ag
bead
patent
ge
healthcar
includ
ce
ligand
copolym
chain
vinyl
sulfon
nvinyl
pyrrolidon
affin
ligand
compris
igbind
domain
protein
protein
z
multimod
ligand
compris
q
group
hydrophob
ring
structur
altern
nmethyl
nbenzyl
ethanolamin
ligand
commerci
capto
adher
note
howev
refer
made
virus
exampl
illustr
biomolecul
separationpurif
use
new
cec
afc
mmc
adsorb
anoth
trend
manufactur
core
bead
resin
alli
size
separ
bind
chemistri
singl
matrix
exemplifi
commerci
core
resin
see
tabl
ag
bead
core
function
hydrophob
interact
ligand
eg
c
c
ligand
particularli
octyl
ligand
proteinac
affin
ligand
eg
protein
protein
l
novel
coreshel
adsorb
test
viru
iav
purif
concentr
cell
cultur
lysat
remov
viral
contamin
mab
sampl
shown
protein
core
bead
prototyp
better
viru
bacteriophag
reduct
perform
mabselect
chosen
refer
resin
anoth
type
core
bead
adsorb
develop
upfront
chromatographi
copenhagen
denmark
adsorb
consist
spheric
bead
tungsten
carbid
core
functionaliz
crosslink
ag
outer
shell
allow
high
process
flow
rate
ebac
protein
captur
yet
appli
viral
particl
process
dextran
use
surfac
extend
bind
q
group
crosslink
ag
cla
bead
aec
media
ge
healthcar
q
xl
q
xl
q
bind
weakstrong
ie
group
crosslink
cel
bead
cellufin
max
iec
resin
manufactur
jnc
clabas
aec
media
wide
appli
viral
particl
purif
see
tabl
cellufin
maxbas
media
iec
pafc
see
far
diversifi
toward
manufactur
biopharmaceut
fujifilm
corpor
tokyo
japan
patent
mmc
carrier
consist
commerci
crosslink
agbas
matrix
seph
bead
dextran
coat
function
protein
c
weak
ce
group
mmc
resin
show
better
igg
purif
effici
hcp
elimin
commerci
mabselect
sure
cla
protein
ligand
cellufin
max
sr
bear
strong
ce
group
viral
clearanc
studi
new
cecafc
resin
yet
perform
sec
matric
ge
healthcar
also
contain
dextran
crosslink
epichlorohydrin
allyl
dextran
n
nmethylenebisacrylamid
togeth
cla
composit
matric
clabas
dextrancontain
media
except
earli
sephadex
sec
resin
frequent
implement
viral
particl
purif
process
see
tabl
flow
properti
composit
dextrancla
sec
medium
improv
maintain
resolut
appli
dextranas
treatment
dextranasetr
resin
display
improv
pressur
flow
compar
superdex
refer
resin
innov
manufactur
process
crosslink
dextran
bead
employ
particul
chromatographi
purif
biomolecul
patent
process
advantag
avoid
use
halogen
aromat
solvent
commonli
use
prior
art
process
dextran
sulfat
use
ligand
coupl
cla
substrat
devir
pafc
resin
launch
year
ago
ge
healthcar
capto
devir
may
potenti
replac
proven
cellufin
sulfat
purif
process
yellow
fever
viru
vero
cell
cultur
pafc
step
follow
capto
core
mmc
addit
effort
improv
column
chromatographi
media
r
also
direct
toward
new
method
purifi
virusesvlp
use
commerci
chromatograph
materi
illustr
latter
patent
exampl
use
deae
seph
ff
aec
purifi
human
calicivirus
norovirus
sapovirus
capto
core
core
bead
mmc
purif
respiratori
syncyti
viru
gener
conclus
review
two
preced
one
materi
base
natur
ps
either
crude
chemic
modifi
essenti
wide
implement
tool
human
struggl
virus
appear
survey
three
widespread
ps
name
agaros
cellulos
chitosan
preval
use
manufactur
materi
antivir
applic
sensu
lato
agaros
deriv
agar
third
major
seawe
ps
produc
worldwid
behind
carrageenan
algin
ag
basic
compon
arrow
particul
resin
column
chromatographi
use
viral
vaccin
purif
ensur
viral
safeti
biopharmaceut
industri
bioprocess
academ
r
studi
way
cellulos
widespread
ps
veget
kingdom
use
chromatographi
resin
also
ma
antivir
applic
furthermor
celbas
materi
wide
present
viral
filter
current
use
viru
filtrat
biopharmaceut
environment
water
sampl
individu
protect
equip
airborn
viral
pathogen
chitosan
obtain
deacetyl
chitin
extract
shell
marin
crustacean
widespread
ps
anim
kingdom
second
abund
natur
polym
cel
limit
util
chromatographi
media
eg
composit
monolith
chitosan
extens
use
micronanocarri
deliveri
antivir
drug
vaccin
current
antivir
applic
psbase
materi
involv
one
big
three
natur
biopolym
permiss
elsevi
citat
count
obtain
len
patent
databas
wwwlensorglenssearch
appli
follow
queri
titl
abstract
left
right
column
chromatographi
chromatographi
simul
move
bed
chromatographi
monolith
membran
chromatographi
membran
adsorb
chromatographi
expand
bed
continu
chromatographi
scale
reason
citat
count
column
chromatographi
divid
date
rang
origin
xaxi
year
includ
latest
date
insert
show
number
grant
patentspat
applic
publish
latest
date
associ
chromatographi
techniqu
virus
queri
complet
viru
viral
v
b
time
evolut
patentspat
applic
associ
main
chromatographi
mode
virus
publish
last
twenti
citat
count
obtain
len
patent
databas
appli
follow
queri
titl
abstract
left
right
affin
chromatographi
v
ion
exchang
chromatographi
v
size
exclus
chromatographi
v
hydrophob
interact
chromatographi
v
mix
mode
chromatographi
v
data
rang
tabl
column
chromatographi
procedur
use
psbase
materi
viral
particl
purif
chromatograph
purif
step
tabl
brief
descript
highli
cla
ag
seph
xl
highli
cla
ag
dextran
surfac
extend
rigid
highli
cla
optim
pore
structur
improv
pressureflow
properti
ge
healthcar
composit
matrix
dextran
coval
bound
highli
cla
ge
healthcar
hr
high
resolut
sf
superfin
bead
allyl
dextran
crosslink
n
nmethylenebisacrylamid
poli
allyl
dextran
con
ge
healthcar
cla
contain
quartz
core
provid
requir
high
densiti
stabl
bed
expans
ge
healthcar
ag
bead
kd
exclus
limit
manufactur
use
proprietari
method
biowork
uppsala
sweden
